Page last updated: 2024-08-24

emtricitabine and Birth Weight

emtricitabine has been researched along with Birth Weight in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Clark, R; Desmond, AC; Govender, V; Gray, G; Lombard, C; Mhlongo, O; Moodley, D; Naidoo, K; Naidoo, M; Newell, ML; Rooney, JF; Sebitloane, M	1

Trials

1 trial(s) available for emtricitabine and Birth Weight

Article	Year
Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial. The lancet. HIV, 2023, Volume: 10, Issue:3 Topics: Adenine; Anti-HIV Agents; Birth Weight; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Pre-Exposure Prophylaxis; Pregnancy; Premature Birth; South Africa; Stillbirth; Tenofovir; Treatment Outcome	2023

Article

Year

Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial.

The lancet. HIV, 2023, Volume: 10, Issue:3

Topics: Adenine; Anti-HIV Agents; Birth Weight; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Pre-Exposure Prophylaxis; Pregnancy; Premature Birth; South Africa; Stillbirth; Tenofovir; Treatment Outcome

2023